Immunogenetic predictors of a rapid virologic response to antiviral therapy in patients with chronic hepatitis C


Cite item

Full Text

Abstract

Aim. To determine the correlation between interleukin 28B (IL28B) gene polymorphism in patients with chronic hepatitis C (CHC), the presence or absence a rapid virologic response to antiviral therapy, and a number of immunological characteristics as a basis for a personalized approach to treating the patients. Subjects and methods. Seventeen CHC patients infected with hepatitis C virus genotype 1b were examined and underwent genetic testing for IL28B gene polymorphism for rs12979860 (CC, CT or TT genotypes) and rs8099917 (TT, TG or GG genotypes) using the modified method of adjacent samples, which revealed single nucleotide substitutions in the genes. Their immunological parameters were identified by a flow cytometry technique by taking into account whether a rapid virologic response had been achieved. Results. The key phenomena of a rapid virologic response in the representatives of different IL28B genotypes are the nonspecific proliferative activity of blood natural killer cells before treatment, as well as the count of regulatory T cells before and 4 weeks after therapy start. Conclusion. To predict the efficiency of antiviral therapy for CHC, it is desirable to supplement genetic studies with immunological data.

Full Text

Иммуногенетические предикторы быстрого вирусологического ответа на противовирусную терапию больных хроническим гепатитом С. - Резюме. Цель исследования. Определение соответствия между полиморфизмом гена интерлейкина 28В (IL28B) у больных хроническим гепатитом С (ХГС), наличием или отсутствием у них быстрого вирусологического ответа (БВО) на противовирусную терапию и рядом иммунологических характеристик как основы для создания персонифицированного подхода к лечению пациентов. Материалы и методы. Обследовали 17 больных ХГС, инфицированных вирусом гепатита С (HCV) генотипа 1b, которым выполнено генетическое тестирование - определение полиморфизма гена IL28B по rs12979860 (генотипы СС, СТ или ТТ) и rs8099917 (генотипы ТТ, ТG или GG) с помощью модифицированного метода "примыкающих проб", выявляющего однонуклеотидные замены в генах; охарактеризованы иммунологические параметры методом проточной цитофлуориметрия с учетом достижения быстрого вирусологического ответа. Результаты. Ключевыми феноменами быстрого вирусологического ответа у представителей разных генотипов IL28B являются неспецифическая пролиферативная активность естественных киллеров крови до лечения, а также число регуляторных Т-клеток до лечения и через 4 нед от его начала. Заключение. Для прогноза эффективности противовирусной терапии ХГС генетические исследования желательно дополнять иммунологическими данными.
×

References

  1. Козлов В.К., Стельмах В.В., Радченко В.Г. Хронический гепатит С: иммунопатогенез, аспекты диагностики и современная стратегия комплексного лечения. СПб.: Альтер Эго; 2009.
  2. Покровский В.И., Жербун А.Б. Вирусные гепатиты в Российской Федерации. Аналитический обзор. 8-й выпуск. СПб.: ФБУН НИИЭМ им. Пастера; 2011.
  3. Fung J., Lai C.L., Yuen M.F. Hepatitis B and C virus-related carcinogenesis. Clin Microbiol Infect 2009; 15 (11): 964-970.
  4. Pham T.N., Michalak T.I. Occult persistence and lymphotropism of hepatitis C virus infection. World J Gastroenterol 2008; 14 (18): 2789-2793.
  5. Stauber R.E., Lackner C. Noninvasive diagnosis of hepatic fibrosis in chronic hepatitis C. World J Gastroenterol 2007; 13 (32): 4287-4294.
  6. Craxi A. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55 (2): 245-264.
  7. Ge D., Fellay J., Thompson A.J. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461 (7262): 399-401.
  8. Suppiah V., Moldovan M., Ahlenstiel G. et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41 (10): 1100-1104.
  9. Tanaka Y., Nishida N., Sugiyama M. et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41 (10): 1105-1109.
  10. Thomas D.L., Thio C.L., Martin M.P. et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009: 461 (7265): 798-801.
  11. Ridruejo E., Solano A., Marciano S. et al. Genetic variation in interleukin-28B predicts SVR in hepatitis C genotype 1 Argentine patients treated with PEG IFN and ribavirin. Ann Hepatol 2011; 10 (4): 452-457.
  12. Darling J.M., Aerssens J., Fanning G. et al. Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. Hepatology 2011; 53 (1): 14-22.
  13. Clark P.J., Thompson A.J., McHutchison J.G. IL28B Genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies. Am J Gastroenterol 2011; 106 (1): 38-45.
  14. Billerbeck E., Bottler T., Thimme R. Regulatory T cells in viral hepatitis. World J Gastroenterol 2007; 13 (36): 4858-4864.
  15. Miyaaki H., Zhou H., Ichikawa T. et al. Study of liver-targeted regulatory T cells in hepatitis B and C virus in chronically infected patients. Liver Int 2009; 29 (5): 702-707.
  16. Yoshizawa K., Abe H., Kubo Y. et al. Expansion of CD4(+)CD25(+)FoxP3(+) regulatory T cells in hepatitis C virus-related chronic hepatitis, cirrhosis and hepatocellular carcinoma. Hepatol Res 2010; 40 (2): 179-187.
  17. dos Santos D.C., Neves P.C., Azeredo E.L. et al. Activated lymphocytes and high liver expression of IFN-γ are associated with fulminant hepatic failure in patients. Liver Int 2012; 32 (1): 147-157.
  18. Tatsumi T., Takehara T., Miyagi T. et al. Hepatitis C virus-specific CD8+ T cell frequencies are associated with the responses of pegylated interferon-α and ribavirin combination therapy in patients with chronic hepatitis C virus infection. Hepatol Res 2011; 41 (1): 30-38.
  19. Zhang Y., Liu Y., Zhao Y. et al. Hepatitis C virus nonstructural protein specific T cells are associated with virological responses to combination therapy in chronic HCV patients. Liver Int 2011; 32 (1): 102-109.
  20. Rath P.C., Aggarwal B.B. Antiproliferative effects of IFN-alpha correlate with the downregulation of nuclear factor-kappa B in human Burkitt lymphoma Daudi cells. J Interferon & Cytokine Res 2001; 21 (7): 523-528.
  21. Vyas K., Brassard D.L., DeLorenzo M.M. et al. Biologic activity of polyethylene glycol12000-interferon-alpha2b compared with interferon-alpha2b: gene modulatory and antigrowth effects in tumor cells. J Immunother 2003; 26 (3): 202-211.

Copyright (c) 2012 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies